Pricing Log in Create free account

Editas Medicine, Inc. (EDIT) vs Relmada Therapeutics, Inc. (RLMD)

Editas Medicine, Inc. and Relmada Therapeutics, Inc. are both Biotechnology companies. Relmada Therapeutics, Inc. is the larger, with a market value of $455.5M against $399.3M — 1.1× the size. Relmada Therapeutics, Inc. has the higher net margin (0.00% vs −157.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Relmada Therapeutics, Inc. leads on 9 and Editas Medicine, Inc. on 3.

Valuation

Metric EDIT RLMD Biotechnology median
P/E n/m n/m 10.64
P/S 6.60 n/m 9.59
P/B 2.95 2.32 2.15
Price to free cash flow n/m n/m 26.07
EV/EBITDA n/m n/m 0.65
EV/Sales 2.79 n/m 9.45
Earnings yield (28.85%) (22.37%) (34.69%)
Free cash flow yield (38.78%) (26.54%) (24.02%)

Profitability

Metric EDIT RLMD Biotechnology median
Gross margin 100.00% 0.00% 65.59%
Operating margin (161.39%) 0.00% 0.00%
Net margin (157.32%) 0.00% 0.00%
Free cash flow margin (255.88%) 0.00% 0.00%
Return on equity (118.82%) (55.66%) (51.96%)
Return on assets (33.02%) (51.57%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric EDIT RLMD Biotechnology median
Revenue growth (TTM) 20.83% — 4.59%
EPS growth (last fiscal year) 37.50% 45.28% 29.88%
Revenue growth, 5-year CAGR (14.89%) — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric EDIT RLMD Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.19 29.52 4.86
Net debt to EBITDA 0.94 1.57 1.01

Dividend

Metric EDIT RLMD Biotechnology median
Dividend yield — — 0.38%
Payout ratio — — —

Size

Metric EDIT RLMD Biotechnology median
Market cap 399.31m 455.48m 174.29m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack